The markets closed mixed with the Dow rising 30 points to 21,813 after Federal Reserve chair Janet Yellen defended regulations enacted after the financial crises of 2007. Nasdaq lost 5 points to 6,265.
On the upside
The Food and Drug Administration approved Adamas Pharmaceuticals' (Nasdaq: ADMS) GOCOVRI to treat dyskinesia in patient with Parkinson's disease.
Shares of Abercrombie & Fitch (NYSE: ANF) extended its gains.
Xoma (Nasdaq: XOMA) licensed the global commercial rights for gevokizumab to Novartis.
On the downside
A court in Guatemala upheld the license suspension for Tahoe Resources' (NYSE: TAHO) Escobal project.
Xtract Research analyst Valerie Potenza wrote that Hertz Global (NYSE: HTZ) may have defaulted on its debt when it cancelled a plan to refinance bonds.
Fourth quarter earnings plunged for Aceto (Nasdaq: ACET).
In the broad market, advancing issues outpaced decliners by a margin of more than 2 to 1 on the NYSE and by a margin of more than 3 to 2 on Nasdaq. The broader S&P 500 rose 4 points to 2,443. Bitcoin surged $76 to $4,310.
